96 results about "Neuroblastoma cell" patented technology

Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular immunotherapy of CE7+ neuroblastoma are disclosed. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain FvFc:ζ receptor where Fv designates the VH and VL chains of a single chain monoclonal antibody to CE7 linked by peptide, Fc represents a hinge —CH2—CH3 region of a human IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. DNA constructs encoding a chimeric T-cell receptor and a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor are also disclosed.

The invention discloses application of MYOZ1 in diagnosing and treating parkinsonism, belonging to the technical field of new application of genes. The experiment proves that the MYOZ1 gene expression in the blood of a parkinsonism patient is enhanced as compared with a normal person, which indicates that the MYOZ1 expression level in the blood can be detected to diagnose whether a subject suffers from parkinsonism. The in-vitro MTT experiment detect that the MYOZ1 gene expression is not beneficial to growth of human neuroblastoma cells. Therefore, the MYOZ1 has favorable development and application prospects in preparing products for diagnosing and treating parkinsonism.

A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155 tumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.

The invention relates an anticancer active part of fructus terminaliae billericae, and a preparation method of the anticancer active part. The invention comprises extraction of the part containing active components, study of a process for enriching by adopting macroporous absorption resin, identification of the active components in the active part, and use of the active part in in-vivo or in-vitroinhibition of liver cancer HepG2, lung cancer A549, lung adenocarcinoma NCI-H1703, gastric cancer BGC823, osteosarcoma cell MG-63, colorectal cancer HCT116, breast cancer MCF-7, neuroblastoma cells shsy5y, kidney cancer ACHN, normal liver cells L02, human breast ductal carcinoma cells ZR75-1, human colorectal adenocarcinoma cells Colo-205, human breast ductal carcinoma cells BT-474, human breastcancer cells T-47D, human cervical cancer cell line HeLa, liver cancer cells H22, and the like. The enrichment method applying the macroporous absorption resin to the anti-cancer active part of the fructus terminaliae billericae is simple in process, safe, non-toxic and low in production cost, and can be used for industrial production, thus having a great economic benefit and higher generalizationperformance.

Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.

The invention discloses a pyrazolopyrimidine-type compound. The structural general formula of the pyrazolopyrimidine-type compound is shown as formula (I). The invention further discloses a preparation method of the pyrazolopyrimidine-type compound and application of the pyrazolopyrimidine-type compound in preparation of antitumor drugs. The provided pyrazolopyrimidine-type compound can effectively inhibit multipletumor cells, including human breast cancer cells, human lung cancer cells, human hepatoma carcinoma cells, human neuroblastoma cells and the like, has high antitumor activity and canbe applied to preparation of the antitumor drugs.

The invention discloses a phenylpropanoid compound, and a preparation method and application thereof. The phenylpropanoid compound is separated from tobacco and has a structure shown in the specification, wherein R represents hydrogen or methyl. The preparation method of the phenylpropanoid compound comprises the steps of extraction, silica gel column chromatography and separation through high-pressure liquid chromatography, and comprises the following specific steps: pulverizing a plant sample, extracting, filtering, concentrating to obtain an extract, performing chromatography, eluting, concentrating, and performing further separation and purification on the (8:2) part to obtain the phenylpropanoid compound. The phenylpropanoid compound can be applied in the preparation of antitumor drugs for inhibiting human bone marrow neuroblastoma cell strains SHSY5Y. According to the invention, the compound is simple in structure and favorable in antitumor activity and can be artificially synthesized easily; and the compounds 1 and 2 show remarkable inhibition activity on SHSY5Y tumor cell strains, and the corresponding IC50 (half maximal inhibitory concentration) values are respectively 1.5 and 2.2 mu M.

A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155 tumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.

The invention discloses a fluorescent probe and a kit for carrying out differential diagnosis on leukemia and bone marrow metastasis of rhabdomyosarcoma and neuroblastoma by using flow cytometry. The fluorescent probe comprises four fluorescence labeled antibodies; the four fluorescence labeled antibodies comprise a GD2 antibody, a CD90 antibody, a CD45 antibody and a CD56 antibody which take fluorescence labels; the different antibodies take the different fluorescence labels. The kit comprises a probe solution, a hemolytic agent, a phosphate buffer and a positive standard product. The fluorescent probe can be respectively and specifically combined with cells of the rhabdomyosarcoma and the neuroblastoma in bone marrow and original cells of acute leukemia; three tumor cells which are common in the child bone marrow, such as the bone marrow metastasis of the rhabdomyosarcoma and the neuroblastoma and the leukemia cells, can be rapidly and accurately identified by the flow cytometry, so as to guide clinical treatment; the application prospect is very good.

The invention relates to the technical field of biomedicine, in particular to a novel target resistant to Japanese encephalitis virus (JEV) infection and application. Human neuroblastoma cells (SK-N-SH) are taken as target cells, RNA technology is adopted to reduce expression of host protein of the target cells to find host factors capable of effectively inhibiting JEV-infected human neuroblastoma cells (SK-N-SH) so as to protect functions of a nerve system and prevent virus from infecting a central nerve system to cause inflammation. The invention provides application of Cofilin in preventing and treating JEV infection, and experiments find that Cofilin plays an important role in JEV-infected SK-N-SH, and JEV infection can be inhibited remarkably by reducing expression of Cofilin. The invention further provides application of Cofilin in preparing drug for preventing or treating JEV infection.

The invention relates to the medical technical field, in particular to a pentacyclic triterpene compound which is separated to be obtained from a ranunculaceae plant of pulsatilla cernua (Thunb.) Bercht.et Opiz, and the chemical structural formula is shown in the accompanying drawing, wherein glc, rha and ara respectively represent beta-D-glucopyranose, alpha-L-pyrane rhamnose and alpha-L-pyrane arabinose, and the compounds A and B are respectively a new compound. Cell experiments in vitro show that the compound has a remarkable protection function to neuroblastoma cell strain SH-SY5Y induced by A beta (25-35). The compound disclosed by the invention has the advantages of simpleness in preparation and remarkable activity. The invention provides the new compound for preventing and curing AD (Alzheimer's Disease). In the invention, the glc, rha and ara respectively represent beta-D-glucopyranose, alpha-L-pyrane rhamnose and alpha-L-pyrane arabinose.

The invention discloses a series of amino acid derivatives prepared by using diosgenin as a lead compound through corresponding chemical reaction. Solubility test finds that the solubility of derivatives is increased compared with the raw material medicine of diosgenin; and the pharmacological experiments prove that the diosgenin amino acid derivatives have in vitro antitumor activity, have different degrees of growth inhibition on human colon cancer cell Caco-2, human gastric carcinoma cell MGC-709, human lung adenocarcinoma cell SPC-A-1 and human neuroblastoma cell SH-SY5Y, and have anti tumor activity similar to that of a nuclear parent compound diosgenin.

The invention relates to the cell transdifferentiation technology in the field of cell research, in particular to a method for inducing neuroblastoma cells to be differentiated to nerve cells. The neuroblastoma cells are cultured for 3-7 days through an inducing culture medium, and then the nerve cells are obtained; the inducing culture medium is obtained by adding retinoic acid to a neural stem cell condition culture solution to 10 micrometers; a complete culture medium including a DMEM / F12 basic cukture mediam, B27, bFGF, EGF, heparn sodium, L-glutamine and mycillin is used for culturing the neural stem cells, the complete culture medium is replaced by a half after culturing is conducted for three days, and the replaced culture solution is the neural stem cell condition culture solution. By means of the method, the differentiation efficiency is improved, and the maturity of the cells and growth of neural synapses of nerve cells are also improved. The cell apoptosis in SH-SY5Y treated through RA can be inhibited.

The invention discloses novel application of forsythin belonging to active components of natural medicinal plants, and particularly relates to application of forsythin as the only active ingredient to preparation of a medicine for improving a cognitive function and treating Alzheimer's diseases. Animal and cell research results indicate that the forsythin has the exact function of improving the cognitive function and can remarkably improve the spatial learning and memory ability of animals in an aging and Alzheimer's disease model, the level of a center monoamine neurotransmitter of an old-aged animal is increased, the genetic expression of presenilin 2 in a rat brain of an Alzheimer's disease model is reduced, and the survival rate of neuroblastoma cells induced by beta-amyloid protein is increased. The forsythin is matched with relevant auxiliary materials, a health care product or a medicine for purposefully improving the cognitive function and treating the Alzheimer's diseases can be prepared by a conventional preparation method, and the health care product and the medicine can be used for delaying and improving relevant diseases of cognitive hypofunction such as the course of the Alzheimer's diseases, enhancing the healthy quality and the life quality of old people and realizing a healthy aging social value.

PL37 (RAARISLGPRCIKAFTE [SEQ ID NO: 2]) is an Antisense Homology Box peptide composed of amino acids 37 to 53 of C5a-anaphylatoxin. Complementary peptides, ASGAPAPGPAGPLRPMF (Pep-A [SEQ ID NO: 1]) and ASTAPARAGLPRLPKFF (Pep-B [SEQ ID NO: 3]) were designed and characterized. Pep-A bound to PL37 and to C5a with very slow dissociation, whereas Pep-B failed to bind at all. C5a was inactivated by 7 nM or more of Pep-A and this concentration of Pep-A inhibited induction of intracellular Ca++ influx in neutrophils. Patch clamp studies also showed the effectiveness of Pep-A in C5a-receptor-expressing neuroblastoma cells. Pep-A administration prevented rats from C5a-mediated rapid lethal shock. A-Pep-A (Pep-A acetylated with alanine at the amino-terminus) was more stable in vivo and showed stronger inhibition of inflammatory reactions in mice and rats. Chemical modification of Pep-A (e.g., acetylation, or single or multiple amino acid replacement, insertion, or deletion within the native Pep-A sequence) will yield effective inhibitors, and will often improve inhibitory function on C5a anaphylatoxin. In such modified constructs it will often be desired to conserve some or all 5 prolines found in Pep-A to preserve inhibitory function on C5a.

The invention relates to the technical field of biomedicine, and particularly relates to a novel target preventing enterovirus 71 infection and applications thereof. Through adopting a human neuroblastoma cell (SH-SY5Y) as a target cell, and reducing expression of target cell host protein by adopting an RNA interference technique, a host factor effectively inhibiting EV71 infection of the human neuroblastoma cell (SH-SY5Y) is searched so as to prevent central nervous system virus infection and reducing damage to the nerve system. Experiments show that vesicle-associated membrane protein 1 (called as VAMP1 for short) plays an important role in EV71 infection of the human neuroblastoma cell (SH-SY5Y) and EV71 infection can be obviously inhibited by reducing expression of the VAMP1. The invention provides applications of the VAMP1 in preparation of medicines preventing and treating the enterovirus 71 infection.

The invention belongs to the field of medicine, and relates to an aromatic acid compound separated from dry mature seeds of Prunuspersica (L.) Batsch or Prunusdavidiana (Carr.) Franch. and application of the aromatic acid compound in medicaments for preventing and treating senile dementia. The compound has the following structure, and is prepared by the steps of extraction, concentration, extraction, concentration and purification; and the compound has an obvious protective effect on damage of Abeta (25-35)-induced neuroblastoma cell strains SH-SY5Y, and has an effect of preventing and treating the senile dementia.

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

The invention provides a preparation method and a use of a medicine over-expressing a PCNP gene. The medicine includes a plasmid over-expressing the PCNP gene and a PCNP protein obtained through the over-expression of the PCNP gene. The construction method of the plasmid over-expressing the PCNP gene comprises the following steps: designing a primer according to the sequence of the PCNP gene, andcarrying out PCR amplification on a target gene; carrying out enzyme digestion on restriction enzyme digestion sites Xho I and Kpn I in a GV230 vector to form a linearized GV230 vector; and connectingthe target gene with the linearized GV230 vector to construct a GV230-PCNP vector which is the plasmid over-expressing the PCNP gene. When the medicine over-expressing the PCNP gene is used in humanneuroblastoma cells, the overexpression of the PCNP gene in the human neuroblastoma cells can promote apoptosis, inhibit cell growth, inhibit cell migration and inhibit the growth of human neuroblastomas.

The invention provides a botanical drug active part of aquilaria sinensis (Lour.) Spreng., a preparation method thereof, a pharmaceutical composition composed of the active part, and application of the botanical drug active part and the pharmaceutical composition in preparation of drugs for treating tumors or cancers. The preparation method comprises the following steps: extracting and extracting dried flos aquilaria sinensis by using a solvent to prepare PXS65, PXS66, PXS66-1, PXS66-2 and PXS66-3; the pharmaceutical composition has remarkable inhibitory activity on cancer cell strains, such as lung cancer SPC-A-1 cells, lung cancer NCI-H520 cells, lung cancer A549 cells, cervical cancer HeLa cells, human neuroblastoma SH-SY5Y cells, ovarian cancer SK-OV-3 cells, leukemia MT4 cells, prostate cancer PC-3 cells, liver cancer SMMC-7721 cells, breast cancer MDA-MB-231 cells, lung cancer NCI-H446 cells, lung cancer taxol drug-resistant strain A549 / Taxol cells and the like. The flos aquilaria sinensis extract disclosed by the invention provides a new choice for drugs for treating or preventing tumors or cancers and drugs for improving tumor or cancer drug resistance.

The invention provides a construction method of a stable cell line realizing FTH1 gene controlled expression. The construction method comprises the following steps: (1) acquiring FTH1 genes; (2) transferring the FTH1 genes into a Tet-On vector to obtain recombinant plasmids; (3) constructing the recombinant plasmids into a lentiviral vector; (4) inoculating human neuroblastoma cells, after the cell fusion reaches 40-50%, adding a safe medium containing lentivirus liquid 0.8 [mu]l / ml (the titer is 1X10<9>TU / ml) and polybrene 5 [mu]g / ml, and polyethylene glycol 0.5-1 [mu]g / ml, and placing the safe medium into an incubator for culturing for 20-24 h; and (5) after cell passage, and the cell fusion reaches 50-60%, adding a medium containing 8 [mu]g / ml puromycin and treating for 7d, then adding a medium containing 4 [mu]g / ml puromycin and screening for 3d, and thus obtaining the stable cell line capable of inducing expression of the FTH1 genes, and the stable cell line is named SK-N-SH / Tet-on / FTH1. With the adoption of the construction method, the expression level and the expression time of FTH1 are accurately regulated, so that FTH1 is expressed when MR imaging is needed, and is turned off when MR imaging is not needed.

The invention relates to an extraction method of an antioxidant and an application in protection of nerve cells against oxidation by utilizing the antioxidant, belonging to the technical field of biological medicines. The extraction method disclosed by the invention comprises the following steps of: taking myricaria laxiflora as a raw material, taking ethanol as an extraction solvent, performing Soxhlet extraction, performing cold leaching on a crude extraction solution with HCl, adjusting the pH with saturated NaCO3, extracting with chloroform, performing chloroform-methanol gradient elution by silica gel column chromatography, performing Sephadex LH-20 gel column methanol elution, and further performing crystallization and re-crystallization to obtain the antioxidant. The antioxidant is identified as 3, 4-dimethoxy-5-methylparaben by 1H-NMR and 13C-NMR, the molecular formula is C10H12O5, and the anti-oxidation property and the free radical scavenging activity are stronger. The concentration of the antioxidant is 0.5-12.5mu g / mL, when the dosage is 100mu L, the toxicity of the natural antioxidant against SH-SY5Y cells is less than 3.4%, the relative survival rate against human neuroblastoma cells SH-SY5Y after oxidative damages by hydrogen peroxide is 50-80%, and the antioxidant has a better anti-oxidation protection effect in comparison with PG (propyl gallate), can be used as a natural non-toxic antioxidant and can be applied to the fields of foods, medicines, cosmetics and the like.

The invention discloses a novel folate receptor targeted liposome, which can exclusively inhibit growth of cells of neuroblastoma and consists of distearoylphosphatidylcholine, cholesterol, 1,2-dioleic-3-dimethyl amide propane, polyethylene glycol-CerC16, folate and siRNA of MYCN gene. The liposome has high delivery efficiency in cells of neuroblastoma where a folate receptor is highly expressed and the finally proportion of liquid / oligonucleotides achieves 0.15-0.25 (w / w). The novel liposome maintains the objective siRNA after general administration for a considerably long period of time in blood circulation. The study represents that the targeted liposome carried with siRNA gene, which is served as the product of the invention, is delivered to LA-N-5 cells by the folate receptor, which obviously inhibits MYCN gene expression and cell growth. The liposome has strong capacity of inhibiting cells of neuroblastoma where the folate receptor is over-expressed and can be used as a medicinefor potential targeted treatment of neuroblastoma.

The invention discloses a cyclodepsipeptide compound which has a structural formula (I) shown in the specification. The compound can be prepared by separating and purifying fermentation products of anendophytic fungus Pseudopithomyces sp. of leaves of a mangrove plant, namely sonneratia caseolaris. In vitro tests show that the cyclodepsipeptide compound has an obvious cell proliferation inhibition effect on HELA (human cervical carcinoma cell) strains, A549 human lung cancer cell strains and SHSY5Y human bone marrow neuroblastoma cell strains and can be used for preparing antitumor drugs.

The invention provides novel gangliosides and mixtures of novel gangliosides, and drug products containing the same. The invention also provides cells induced to over-express one or more gangliosides. The invention further provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

The invention discloses 2,3,6-trideoxyglycosyl demethylepipodophyllotoxin compound or pharmaceutically acceptable ester thereof. The chemical structural formula of the 2,3,6-trideoxyglycosyl demethylepipodophyllotoxin compound is as shown in the figure I in the specification, wherein R represents C1-C6 alkyl, -OH, -NH2, NO2 and halogen groups. The compound has the advantage of being capable of remarkably improving the cytotoxic activity on human lung cancer cells (A549), human hepatoma cells (HepG2), human cervical cancer cells (HeLa), human neuroblastoma cells (SH-SY5Y) and oral cancer vinblastine-resistant cells (KB-VCR) compared with clinical medication of etoposide and has the potential of being developed into anti-tumor drugs.

The invention relates to a traditional Chinese medicine composition, in particular to an anti-tumour traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The anti-tumour traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-60 parts of radix astragali, 12-36 parts of rhizoma smilacis glabrae, 15-45 parts of radix pulsatillae, 12-36 parts of cortex phellodendri, 6-18 parts of rhizoma coptidis and 12-36 parts of cortex fraxini. The traditional Chinese medicine composition disclosed by the invention is scientific and reasonable in compatibility, exact in pharmacological activity, good in safety and low in adverse reaction, has anti-tumour activity, and is applied to in-vivo and in-vitro anti-tumour activity of different types of tumours; and it is found that the composition has an obvious anti-tumour effect on human lymphoma cells, lung cancer cells, breast cancer cells, gastric cancer cells, cervical cancer cells, colon cancer cells, esophageal cancer cells, osteosarcoma cells, promyelocytic acute leukemia cells, ovarian cancer cells, multiple myeloma cells, neuroblastoma cells, liver cancer cells, malignant melanoma cells and the like.